Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer’s Disease Research at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.